Tech’s market debutantes overshadowed by Gates-backed pharma stock

We know that tech’s biggest are stronger than before the coronavirus pandemic — but when it comes to stock market debutants, tech companies have been completely overshadowed by a new wave of public biotech and pharmaceutical firms. The only exception is ZoomInfo, the Massachusetts data software and marketing startup that raised nearly $1 billion with its stock offering last week. As of Friday’s market close, ZoomInfo stock was up a tongue-swelling 85% on its initial offer price, making it the most profitable US listing for a tech company so far this year. Still, that’s nothing compared to Schrodinger, a pharma-fused simulation software firm…

This story continues at The Next Web